Robert A. Cormack

Robert A. Cormack

Auto-generated profile, based on publicly available information

Robert A. Cormack

Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2001 in Medical Physics
Verified
Journal Article
Closed access
PDF file
ABAditya Bharatha
Aditya Bharatha
MHMasanori Hirose
Masanori Hirose
NHNobuhiko Hata
Nobuhiko Hata
SWSimon K. Warfield
Simon K. Warfield
MFMatthieu Ferrant
Matthieu Ferrant
CTClare M. C. Tempany
Clare M. C. Tempany

1 December 2001 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SNS Nag
S Nag
JCJ P Ciezki
J P Ciezki
RCR Cormack
R Cormack
SDS Doggett
S Doggett
KDK DeWyngaert
K DeWyngaert
CSClinical Research Committe, American Brachytherapy Society
Clinical Research Committe, American Brachytherapy Society

1 January 2012 in Brachytherapy
Verified
Journal Article
Closed access
SBSushil Beriwal
Sushil Beriwal
DDD. Jeffrey Demanes
D. Jeffrey Demanes
BEBeth Erickson
Beth Erickson
EJEllen Jones
Ellen Jones
JSJennifer F. De Los Santos
Jennifer F. De Los Santos
AVAkila N. Viswanathan
Akila N. Viswanathan

1 October 1998 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ADAnthonyV. D’Amico
AnthonyV. D’Amico
RCRobert Cormack
Robert Cormack
CTClareM. Tempany
ClareM. Tempany
SKSanjaya Kumar
Sanjaya Kumar
GTGeorge Topulos
George Topulos
CCC.NOrman Coleman
C.NOrman Coleman

13 August 2007 in Cancer
Verified
Journal Article
Open access
PDF file
PNPaul L. Nguyen
Paul L. Nguyen
MCMing‐Hui Chen
Ming‐Hui Chen
ADAnthony V. D'AMico
Anthony V. D'AMico
CTClare M. Tempany
Clare M. Tempany
GSGraeme S. Steele
Graeme S. Steele
WSW. Warren Suh
W. Warren Suh
BACKGROUND.: The authors prospectively evaluated the late gastrointestinal (GI) and genitourinary (GU) toxicity and prostate‐specific antigen (PSA) control of magnetic resonance imaging (MRI)‐guided brachytherapy used as salvage for radiation therapy (RT) failure.METHODS.: From October 2000 to October 2005, 25 men with a rising PSA level and biopsy‐proven, intraprostatic cancer at least 2 years after initial RT (external beam in 13 men and brachytherapy in 12 men) who had favorable clinical features (Gleason score ≤7, PSA < 10 ng/mL, negative pelvic and bone imaging studies), received MRI‐guided salvage brachytherapy to a minimum peripheral dose of 137 gray on a phase 1/2 protocol. Estimates of toxicity and cancer control were calculated using the Kaplan‐Meier method.RESULTS.: The median follow‐up was 47 months. The 4‐year estimate of grade 3 or 4 GI or GU toxicity was 30%, and 13% of patients required a colostomy and/or urostomy to repair a fistula. An interval < 4.5 years between RT courses was associated with both outcomes with a hazard ratio of 12 (95% confidence interval [95% CI], 1.4–100; P = .02) for grade 3 or 4 toxicity and 25 (95% CI, 1.1–529; P = .04) for colostomy and/orurostomy. PSA control (nadir +2 definition) was 70% at 4 years.CONCLUSIONS.: The current results indicated that MRI‐guided salvage brachytherapy in men who are selected based on presenting characteristics and postfailure PSA kinetics can achieve high PSA control rates, although complications requiring surgical intervention may occur in 10% to 15% of patients. Prospective randomized studies are needed to characterize the relative cancer control and toxicity after all forms of salvage local therapy. Cancer 2007. © 2007 American Cancer Society.

1 January 2013 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
WNWilfred Ngwa
Wilfred Ngwa
HKHouari Korideck
Houari Korideck
AKAmin I. Kassis
Amin I. Kassis
RKRajiv Kumar
Rajiv Kumar
SSSrinivas Sridhar
Srinivas Sridhar
RCRobert A. Cormack
Robert A. Cormack